沙美特罗替卡松干粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床疗效

Clinical Efficacy of Seretide Dry Powder Inhaler Joint Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease in Stabilization Period

目的：探讨与分析沙美特罗替卡松（舒利迭）干粉吸入剂联合噻托溴铵治疗稳定期慢性阻塞性肺疾病（chronic obstructive pulmonary disease,COPD）的临床疗效。方法：选择2011年1月~2013年1月期间我院治疗的96例稳定期COPD患者,将其随机分成实验组和对照组两组,每组各48例,实验组给予舒利迭干粉吸入剂联合噻托溴铵治疗,对照组单独给予噻托溴铵治疗,疗程为12周,对比分析两组患者肺功能变化以及临床症状及日常生活评分。结果：经过1个疗程的治疗,两组患者的肺功能明显改善,FVC、FEV1及FEV1/FVC指标水平均明显好转,且实验组相比对照组的好转情况更显著,差异具统计学意义（P〈0.01、P〈0.05）;观察组患者的临床症状及日常生活各项指标相比对照组患者均有明显改善,且两组间的差异具有统计学意义（P〈0.01）。结论：相比单独使用噻托溴铵治疗COPD,舒利迭干粉吸入剂联合噻托溴铵治疗临床疗效更为显著,适合临床广泛使用。

Objective：To investigate clinical efficacy of dry powder inhaler Seretide joint tiotropium treatment of chronic obstructive pulmonary disease（COPD）in stabilization period.Methods：96 cases of patients with chronic obstructive pulmonary disease in our hospital from January 2011 to January 2013 were divided into the experimental group（48 cases）,treated by dry powder inhaler Seretide given joint tiotropium therapy and the control group（48 cases）,treated by only tiotropium therapy.Treatment for 12 weeks,the lung function changes and clinical symptoms and daily living scores of two groups were analyzed.Results：After a course of treatment,the lung function of two groups of patients was significantly improved;The indicators of FVC,FEV1 and FEV1/FVC were significantly better than that of before treatment;Compared to the control group,the situation of experimental group improved more significant（P〈0.01,P〈0.05）.The patient’s clinical symptoms and daily life indicators of the experimental group showed significant improvement than that of the control group,（P〈0.01）.Conclusion：Compared to tiotropium alone treatment for COPD,dry powder inhaler Seretide joint tiotropium therapy have significant clinical efficacy.